Search Results - "Papachristos, Apostolos"

Lurbinectedin-induced thrombocytopenia: the role of body surface area by Papachristos, Apostolos, Ratain, Mark J.

“…Lurbinectedin is an alkylating agent approved for the second-line treatment of small cell lung cancer. Although initial studies showed no association between…”
Get full text

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer by Papachristos, Apostolos, Karatza, Eleni, Kalofonos, Haralabos, Sivolapenko, Gregory

“…Vascular endothelial growth factor A (VEGF-A) and intercellular adhesion molecule 1 (ICAM-1) are significant regulators of angiogenesis, an important…”
Get full text

Editorial: Utilization of pharmacogenomics in clinical practice by Papachristos, Apostolos, Cusato, Jessica, Nair, Sujit, Maggo, Simran, Suppiah, Vijayaprakash

Get full text

VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer by Papachristos, Apostolos, Kemos, Polychronis, Katsila, Theodora, Panoilia, Eirini, Patrinos, George P, Kalofonos, Haralabos, Sivolapenko, Gregory B

“…Bevacizumab is used to treat metastatic colorectal cancer (mCRC). However, there are still no available predictors of clinical outcomes. We investigated…”
Get full text

Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment by Karatza, Eleni, Papachristos, Apostolos, Sivolapenko, Gregory B., Gonzalez, Daniel

“…Therapeutic outcomes in patients with metastatic colorectal cancer (mCRC) receiving bevacizumab treatment are highly variable, and a reliable predictive factor…”
Get full text

Direct oral anticoagulant considerations in solid organ transplantation: A review by Salerno, David M., Tsapepas, Demetra, Papachristos, Apostolos, Chang, Jae‐Hyung, Martin, Spencer, Hardy, Mark A., McKeen, Jaclyn

“…For more than 60 years, warfarin was the only oral anticoagulation agent available for use in the United States. In many recent clinical trials, several direct…”
Get full text

Factors incorporated into future survival estimation among Europeans by Papachristos, Apostolos, Verropoulou, Georgia, Ploubidis, George B., Tsimbos, Cleon

“…Subjective survival probabilities are affected by individual-specific judgment and vary by factors known to differentiate actual mortality. The aim of this…”
Get full text

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma by Rischin, Danny, Hughes, Brett G M, Basset-Séguin, Nicole, Schadendorf, Dirk, Bowyer, Samantha, Trabelsi Messai, Sabiha, Meier, Friedegund, Eigentler, Thomas K, Casado Echarren, Victoria, Stein, Brian, Beylot-Barry, Marie, Dalac, Sophie, Dréno, Brigitte, Migden, Michael R, Hauschild, Axel, Schmults, Chrysalyne D, Lim, Annette M, Yoo, Suk-Young, Paccaly, Anne J, Papachristos, Apostolos, Nguyen, Jenny-Hoa, Okoye, Emmanuel, Seebach, Frank, Booth, Jocelyn, Lowy, Israel, Fury, Matthew G, Guminski, Alexander

“…BackgroundCemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of…”
Get full text

Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer by Papachristos, Apostolos, Kemos, Polychronis, Kalofonos, Haralabos, Sivolapenko, Gregory

“…Background Bevacizumab treatment is subject to large interpatient variability in efficacy, which may partly be explained by differences in complex bevacizumab…”
Get full text

Incorporating subjective survival information in mortality and change in health status predictions: A Bayesian approach by Papachristos, Apostolos, Fouskakis, Dimitris

“…Subjective survival probabilities incorporate individuals' view about own future survival and they are associated with actual mortality patterns. The objective…”
Get full text

Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab by Papachristos, Apostolos, Ratain, Mark J.

Get full text

VEGF-A polymorphisms affect the pharmacologic effect of bevacizumab on VEGF-A levels in patients with metastatic colorectal cancer by Papachristos, Apostolos, Kemos, Polychronis, Kalofonos, Haralabos, Sivolapenko, Gregory

“…Abstract only e15505 Background: Bevacizumab treatment presents large interpatient variability in efficacy. Mutations in VEGF-A rs699947 are associated with…”
Get full text

In Reply by Papachristos, Apostolos, Kemos, Polychronis, Kalofonos, Haralabos, Sivolapenko, Gregory

“…This letter to the editor responds to Le Louedec et al. regarding the recently published article on the correlation between bevacizumab exposure and survival…”
Get full text

In Reply by Papachristos, Apostolos, Kemos, Polychronis, Kalofonos, Haralabos, Sivolapenko, Gregory

“…This letter to the editor responds to Le Louedec et al. regarding the recently published article on the correlation between bevacizumab exposure and survival…”
Get full text

In Reply by Papachristos, Apostolos, Kemos, Polychronis, Kalofonos, Haralabos, Sivolapenko, Gregory

“…This letter to the editor responds to Le Louedec et al. regarding the recently published article on the correlation between bevacizumab exposure and survival…”
Get full text

Subjective survival: An assessment of accuracy according to individual social profile by Papachristos, Apostolos, Verropoulou, Georgia

“…The present study aims at identifying traits that relate to the underestimation or the overestimation of survival, using information from a rich dataset, the…”
Get full text

Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics by Papachristos, Apostolos, Patel, Jai, Vasileiou, Maria, Patrinos, George P

“…Drugs' safety and effectiveness are evaluated in randomized, dose-ranging trials in most therapeutic areas. However, this is only sometimes feasible in…”
Get full text

Personalizing chemotherapy dosing using pharmacological methods by Patel, Jai N., Papachristos, Apostolos

“…Purpose Given the toxic nature and narrow therapeutic index of traditional chemotherapeutics, better methods of dose and therapy selection are critical…”
Get full text

Quantifying self-rated age by Verropoulou, Georgia, Papachristos, Apostolos, Ploubidis, George B., Tsimbos, Cleon

“…Chronological age, in conjunction with population life tables, is widely used for estimating future life expectancy. The aims of this study are to estimate a…”
Get full text

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development by Davis, John D., Bravo Padros, Marçal, Conrado, Daniela J., Ganguly, Samit, Guan, Xiaowen, Hassan, Hazem E., Hazra, Anasuya, Irvin, Susan C., Jayachandran, Priya, Kosloski, Matthew P., Lin, Kuan‐Ju, Mukherjee, Kamalika, Paccaly, Anne, Papachristos, Apostolos, Partridge, Michael A., Prabhu, Saileta, Visich, Jennifer, Welf, Erik S., Xu, Xiaoying, Zhao, An, Zhu, Min

“…Subcutaneous (s.c.) administration of monoclonal antibodies (mAbs) can reduce treatment burden for patients and healthcare systems compared with intravenous…”
Get full text